Mr. Ravenscroft has nearly 30 years of experience in the health care industry spanning senior product development and commercial management roles in North America, Europe and Asia. Mr. Ravenscroft joined Lentigen in February 2008. Prior to that, he served as President of Bristol-Myers Squibb's Medical Imaging Business, which he led through a successful sale to Avista Capital Partners LP for $525 million in January 2008. He was also Vice President of Bristol-Myers Squibb's Global Virology Franchise, leading the global launch of Reyataz, a novel HIV drug with annual global sales in excess of $1 billion. Mr. Ravenscroft has held executive and senior positions with DuPont Pharmaceutical's Global HIV Business, where he launched Sustiva, an HIV drug with annual global sales in excess of $1 billion and with Glaxo Wellcome. Mr. Ravenscroft holds a master's degree in Information Science from City University in the United Kingdom and a bachelor's degree in Applied Biology from North East London University.
David Wetherell became Chairman of the Board in April 2005. Mr. Wetherell is a Managing Partner of GBP Capital, a venture capital firm focused on investments in life science companies. Mr. Wetherell's career began with the development of software programs for a variety of industries. He led a leveraged buyout of a direct marketing company, College Marketing Group, and transformed it into CMGI. Under his leadership as CEO of CMGI,, sales rose from $3million to over $1billion annually. Mr. Wetherell started numerous Internet companies, including the first internet venture capital firm for the Internet, @Ventures, which was responsible for providing the initial capital to a number of key early companies, including Lycos, GeoCities (now part of Yahoo), Half.com (a large part of eBay), Vicinity (now, Microsoft's mapping technology), PlanetAll (part of Amazon.com), WebCT, and MyFamily.com (also known as Ancestry.com). Mr. Wetherell was Chairman of CMGI until his retirement in August 2006. Mr. Wetherell has received numerous awards, including Ernst and Young's New England Entrepreneur of the Year in 2000. He obtained his B.A. in Mathematics from Ohio Wesleyan University in 1976 and an honorary doctorate from Bryant University.
Dr. Dropulic has more than 20 years of experience in academia and the biotech industry. Prior to founding Lentigen, he was founder and chief scientific officer of ViRxSys where he successfully led a multidisciplinary team to initiate and complete the first lentiviral vector clinical trial in humans. Previously, Dr Dropulic was an Instructor and then Adjunct Assistant Professor at Johns Hopkins University School of Medicine in Baltimore, Maryland, where he was the first to develop an HIV-based vector targeted to inhibit the replication of the HIV/AIDS virus. Dr. Dropulic was a Fogarty Fellow at the National Institutes of Health where he worked on developing transgenic animals using embryonic stem cell technology, understanding molecular aspects of HIV replication and gene therapy for HIV/AIDS. He obtained his Ph.D. from the University of Western Australia focusing upon how viruses cause disease in the body. Dr Dropulic received his B.Sc. (Hons.) from the University of Western Australia and an MBA from The Johns Hopkins University.
Doug Lind joined the Board of Lentigen in April 2005. Dr. Lind is a Managing Partner of GBP Capital. Dr. Lind was a former Manager Partner of Accendx Management, LLC, an asset management firm focused on the healthcare sector. He was the senior biotechnology equity research analyst at Morgan Stanley from 1997 through 2002 and at PaineWebber from 1995 to 1997. Previously, he was the Managing Director of Lind & Co., a Boston-based biotechnology investment research firm serving institutional clients which he founded in 1991. Dr. Lind is a former Tufts University Clinical Fellow in Medicine and a past member of the American Medical Association Council on Ethical and Judicial Affairs. He has served on numerous national health policy bodies, including the Health Policy Agenda for the American People and the American Medical Association Task Force on Physician Manpower. Dr. Lind is a graduate of Iowa State University in 1982 and the University of Iowa College of Medicine in 1987. From 1990 to 1992, he was a practicing physician in Brookline, Massachusetts. He served as an attending physician at St. Elizabeth's Hospital in Boston, a major teaching affiliate of Tufts University School of Medicine, where he completed his residency in Internal Medicine.
Jack McMullen joined the Board of Lentigen in July 2005. Mr. McMullen is the Managing Principal of Cambridge Meridian Group, a strategy-consulting firm that services Fortune 500 and technology-based companies. Mr. McMullen previously taught business strategy at Harvard Law School. He serves, or has served, on the Boards of three NASDAQ listed technology companies, as well as 12 other privately funded, chiefly technology-oriented companies. From 1993 to 1997, he was an informal advisor to Senator Bill Bradley of New Jersey. In 2004, he was the Republican nominee for the U.S. Senate from Vermont. Mr. McMullen is a Navy veteran who served on the staff of Admiral Rickover overseeing the retrofit of advanced technology reactors into the Navy's nuclear fleet. Mr. McMullen is a Phi Beta Kappa graduate of Columbia University in Applied Physics and Engineering, received a J.D. with Honors from Harvard Law School in 1973 and an M.B.A. with High Distinction from Harvard Business School in 1972, where he was elected a First Year Baker Scholar.
Barrie Carter joined the Board of Lentigen in September 2005. Since 1992, he has been Executive Vice President and Chief Scientific Officer of Targeted Genetics Corporation (TGEN: Nasdaq). From 1970 to 1992, he was employed at the National Institutes of Health (NIH). From 1982 to 1992, he was Chief of the Laboratory of Molecular and Cellular Biology at the National Institute for Diabetes, Digestive and Kidney Diseases (NIDDK). Prior to joining NIDDK, he was a post-doctoral fellow at the Imperial Cancer Research Fund Laboratories in London, England. Dr. Carter serves on the editorial boards of Human Gene Therapy and Virology and is an Associate Editor of Molecular Therapy. From 1995-2000, he was an Affiliate Professor of Medicine at the University of Washington Medical School. Dr. Carter currently serves on the External Advisory Committee at the University of Washington, School of Public Health and Community Medicine, the Keystone Symposia Scientific Advisory Board, and the Board of Directors of the American Society of Gene Therapy. He received his B.Sc. with First Class Honors from the University of Otago, Dunedin, New Zealand in 1966 and his Ph.D. in the Biochemistry Department of the University of Otago Medical School in 1969.
